RUNX1 and acute myeloid leukemia: However, cladribine has shown sensitivity against monocytic LSCs by targeting purine metabolism,28 and homoharringtonine‐based regimens have proven effective in RUNX1–RUNX1T1 AML, both in previous studies and in our findings.29, 30, 31